107342-77-8Relevant academic research and scientific papers
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents
Sohda,Mizuno,Momose,Ikeda,Fujita,Meguro
, p. 2617 - 2626 (2007/10/02)
In the course of further chemical modification of the novel antidiabetic pioglitazone (AD-4833, U-72, 107), a series of 5-[4-(2- or 4- azolylalkoxy)benzyl- or -benzylidene]-2,4-thiazolidinediones was prepared and evaluated for hypoglycemic and hypolipidemic activities in insulin-resistant, genetically obese, and diabetic KKA(y) mice. Replacement of the 2-pyridyl moiety of pioglitazone by a 2- or 4-oxazolyl or a 2- or 4-thiazolyl moiety greatly enhanced in vivo potency. The corresponding 5-benzylidene-type compounds, in which a methine was used as a linker between the benzene ring and the thiazolidinedione ring, also had potent biological activity. Among the compounds synthesized, 5-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxy]benzyl]-2,4-thiazolidinedione (18) exhibited the most potent activity, more than 100 times that of pioglitazone. The synthesis and structure-activity relationships for this novel series of derivatives are detailed.
Thiazolidine derivatives, their production and use
-
, (2008/06/13)
A thiazolidinedione derivative of the general formula: STR1 wherein X is an oxygen or sulfur atom, R1 and R2 each independently is hydrogen or a hydrocarbon residue which may optionally be substituted and R1 and R2 may jointly, together with the oxazole or thiazole ring, form a condensed ring and A is a lower alkylene group; or a salt thereof, are novel compounds, which exhibit in mammals blood sugar- and lipid-lowering activity, and are of value as a therapeutic agent for diabetes and/or therapeutic agent for hyperlipemia.
